Bristol Myers Squibb Company has been preparing for a long time to launch its most recently approved product, the TYK2 inhibitor Sotyktu (deucravacitinib). And with its first dermatology drug, the company has set a big goal – to become the new standard of care for treating psoriasis with an oral therapy, unseating Amgen, Inc.’s established PDE4 inhibitor Otezla (apremilast).
The US Food and Drug Administration approved Sotyktu for the treatment of moderate-to-severe plaque psoriasis on 9 September with a label that does not include the limitations that JAK inhibitors have due to safety concerns. BMS has maintained that although TYK2 is a target within the JAK family, drugs targeting TYK2 do not have the same safety concerns, such as thrombosis
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?